Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

Breast cancer is the second leading malignant disease in females worldwide. Over decades of research, breast cancer classification by molecular subtypes has ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to better outcomes ...

Development of a highly sensitive in vitro system to detect and discriminate between vitamin D receptor agonists and antagonists based on split-luciferase technique.

(OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced encouraging survival outcomes among ...

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.